PathMaker Neurosystems

PathMaker is honored to receive the $25,000 award at the 2026 BioChallenge neuroscience competition on 10/29 in New Orleans! Thanks to NOBIC, sponsors & judges for recognizing our progress toward treating ALS. Congrats to our outstanding fellow finalists! #ALS #BioChallenge2026

PathMaker’s clinical collaborators from BIDMC will present at the 2026 Annual NEALS meeting being held 10/27-10/30 in Clearwater, FL where they will discuss interim results from the CALM trial, funded by the DoD ALSRP program. Join us: meeting.neals.org/currentmee… #ALS #Neurotech

Nader Yaghoubi, M.D., Ph.D., Co-Founder and CEO, was a speaker at the MIT Health Science Technology Forum yesterday, where he highlighted PathMaker’s treatment for ALS. PathMaker thanks the MIT STEX and ILP for the opportunity! #MITSTEX #ModernTherapeutics #ALS #Neuromodulation

PathMaker has been selected to present at the MIT Health Science Technology Forum on 5/11. Dr. Nader Yaghoubi, Co-Founder/CEO, will be giving a talk on “Non-Invasive Treatment of ALS and Neurodegenerative Diseases using Neurotechnology”. More info: ilp.mit.edu/Health26 #ALS

At the MDA Conference this week, Dr. Nader Yaghoubi presented top-line results from the Company’s ALS Early Feasibility Study showing that treatment with the MyoRegulator device was safe/tolerable in ALS patients, with no unexpected changes on clinical endpoints. #MDAConference

PathMaker’s Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be speaking at the 2026 MDA Clinical & Scientific Conference being held March 8-11, 2026 in Orlando, Florida, where he will be discussing final results from PathMaker’s ALS EFS. Join us: mdaconference.org/

PathMaker Neurosystems would like to extend our congratulations to Board Director, John Donoghue, Ph.D., who has been named a 2026 Laureate of the Queen Elizabeth Prize for Engineering. Click to learn more: globenewswire.com/news-relea…

Nader Yaghoubi, M.D., Ph.D. from PathMaker Neurosystems and Seward Rutkove, M.D., Chair of the Department of Neurology at Beth Israel Deaconess Medical Center will be presenting at the NEALS Community Education Webinar this Friday, January 9 at 2 PM EST. #ALS #Neuromodulation

PathMaker’s breakthrough multi-site DCS technology can reduce toxic TDP-43 aggregates in neurons of ALS mice – broadening the applicability of this treatment to the large majority of ALS cases. Findings are being presented at the MNDA Symposium Dec 5-7 in San Diego🔥#ALS

PathMaker's Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be attending NEALS, a leading ALS conference being held October 8-10. PathMaker's clinical collaborators from BIDMC will be presenting a poster on their US Dept. of Defense-funded CALM trial.

Joining leaders at #ALSNexus 2025 in Dallas next week to dive into the latest ALS research, treatments & clinical progress! Excited to connect w/ leaders fighting for a cure. 💪Join the effort: event.alsnexus.org/event/beb… #EndALS